Nordson Earnings Call Transcripts
Fiscal Year 2026
-
Record Q2 sales and earnings driven by broad-based organic growth, strong backlog, and robust cash flow. Guidance for FY26 was raised on continued demand momentum, with all segments contributing and strategic M&A supporting future growth.
-
Record Q1 sales and earnings driven by strong semiconductor demand and broad-based segment growth, with robust cash flow and increased full-year guidance. Margins held steady despite mix and FX headwinds, and capital deployment remained disciplined.
Fiscal Year 2025
-
Record sales and earnings were achieved in fiscal 2025, with strong cash flow enabling share repurchases, debt reduction, and dividend increases. Segment performance was mixed, but order backlogs and end-market trends support a positive 2026 outlook.
-
Q3 sales rose 12% year-over-year to $742 million, with strong contributions from the Atrion acquisition and double-digit organic growth in advanced technology. Record free cash flow enabled debt reduction and share repurchases, while FY25 guidance was modestly improved despite ongoing market uncertainties.
-
Second quarter sales grew 5% year-over-year to $683 million, with strong performance in advanced technology and medical segments, aided by the Atrion acquisition. EBITDA margin reached 32%, and Q3 guidance projects continued growth despite trade uncertainties.
-
Q1 2025 sales declined 3% year-over-year to $615 million, with strong operational margins and cash flow despite soft demand in electronics and industrial markets. Order entry and backlog improved, and the Atrion acquisition contributed positively. Full-year sales are expected at the low end of guidance, but profit delivery remains on track.
Fiscal Year 2024
-
Record FY2024 sales and EBITDA were achieved, driven by acquisitions and operational efficiency, despite organic sales declines in key segments. FY2025 guidance anticipates 2%-7% sales growth, with Atrion as a major contributor and continued margin focus amid cautious end markets.
-
The company outlined a five-year plan targeting 6%-8% annual revenue growth and 10%-12% EPS growth, driven by the Ascend Strategy and NBS Next framework. Portfolio transformation, disciplined M&A, and operational excellence position all segments for above-market growth, with strong cash flow supporting continued investment and flexibility.
-
Q3 sales rose 2% year-over-year to $662 million, with strong IPS segment growth and robust free cash flow supporting dividends, buybacks, and debt reduction. The Atrion acquisition expands the medical portfolio, while FY24 guidance remains unchanged, anticipating ATS segment growth in 2025.